Drug Design and Novel Biomarkers for the Treatment of Gastrointestinal Tumors
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: 15 November 2024 | Viewed by 229
Special Issue Editors
Interests: immunogenetics; pharmacogenetics; immune system; human leukocyte antigen (HLA); HLA-G; colorectal cancer; rectal cancer; gene polymorphisms; proteins expression; molecular targets; clinical outcomes; precision medicine
Interests: pharmacogenetics; colorectal cancer; rectal cancer; gene polymorphisms; molecular targets; clinical outcomes; precision medicine; pharmacogenetic guidelines; ADME genes
Special Issue Information
Dear Colleagues,
Pharmacogenetics plays a key role in personalized cancer treatment. Clinically available pharmacogenetic biomarkers for gastrointestinal (GI) cancers are in genes related to drug metabolism, such as DPYD for fluoropyrimidines and UGT1A1 for irinotecan. Recently, the impact of host variability in immune-related genes on treatment response and toxicity has gained considerable attention, opening innovative perspectives for optimizing the GI therapy, management, and survival of these patients. Immunotherapy requires the discovery of novel biomarkers as effective predictive and prognostic targets.
In this Special Issue, titled “Drug Design and Novel Biomarkers for the Treatment of Gastrointestinal Tumors” we aim to collect recent advances in immune- and pharmaco-related biomarkers, their functional roles, and their relationships with conventional and/or biological drugs used in monotherapy or combination for the treatment of GI cancers.
We welcome researchers to contribute original research and review articles, particularly those highlighting the latest proposed biomarkers for immunotherapy in clinical studies. Studies reporting pharmacological interactions with immune-related factors affecting clinical outcomes in GI cancers are strongly encouraged for their impact on future implementation in clinical practice.
Dr. Lucia Scarabel
Dr. Alessia Bignucolo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunogenetics
- pharmacogenetics
- gastrointestinal cancer
- colorectal cancer
- rectal cancer
- prognostic biomarkers
- genetic susceptibility factors
- precision medicine
- immune system
- clinical implementation
- immunocheckpoint inhibitors
- immunotherapy
- chemotherapy
- radiotherapy
- repurposing drug
- drug design and targeted drugs
- gut microbiome
- gut microbiota-related biomarkers
